Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Abstract Background The use of regorafenib in the treatment of hepatocellular carcinoma (HCC) is widespread. Albumin-Bilirubin (ALBI) has been shown to be a potential prognostic marker for regorafenib treatment, but its prognostic value remains controversial. Therefore, we conducted a meta-analysis...

Descrición completa

Detalles Bibliográficos

Principais autores:	Huilin Xu, Dedong Cao, Dingjie Zhou, Nan Zhao, Xixian Tang, Vishalkumar G. Shelat, Hrishikesh Samant, Sanjaya K. Satapathy, Francisco Tustumi, Giuseppe Aprile, Anbing He, Ximing Xu, Wei Ge
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2023-10-01
Series:	BMC Cancer
Assuntos:	Hepatocellular carcinoma (HCC) Regorafenib Biomarker Albumin-bilirubin (ALBI) Survival
Acceso en liña:	https://doi.org/10.1186/s12885-023-11488-9
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!